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Objectives: The prevalence of both insomnia and cognitive impairment in survivors of breast 
cancer is well documented. Although there are currently effective treatments for insomnia, very 
few, if any, treatments are effective for improving cognitive impairment. This study evaluated 
the feasibility and acceptability of using Cognitive Behavioural Therapy for Insomnia (CBT-I), a 
gold-standard insomnia intervention, for the secondary benefit of improving perceived cognitive 
impairment (PCI) in survivors of breast cancer.  
Methods: We recruited 10 female survivors of breast cancer who resided in St. John’s, 
Newfoundland. Participants underwent 7 weekly sessions of CBT-I treatment and completed 
questionnaires to assess cognitive functioning, sleep, and psychological wellbeing at baseline, 2 
months (post-treatment), and 3- and 6-months following treatment, for a total study time of 8 
months. Repeated measures ANOVAs with pairwise comparisons were conducted to determine 
changes in symptomology.  
Results: Out of 45 participants screened, 10 were both eligible and enrolled, for a recruitment 
feasibility rate of 22%. The intervention was highly acceptable with 100% of enrolled 
participants completing treatment. There were statistically significant improvements in PCI [p < 
.001, Ƞp2 = .546], insomnia [p < .001, Ƞp2 = .739], fatigue [p = .004, Ƞp2 = .379] and depression 
[p = .03, Ƞp2 = .276], over the 8-month study period. Pairwise comparisons revealed significant 
decreases in PCI from baseline to post treatment [p = .006], 3 months [p = .003] and 6 months [p 
= .002]. 
Conclusions: CBT-I seems to be an acceptable and potentially efficacious option for improving 
PCI in survivors of breast cancer, but future adequately powered randomized controlled trials are 
needed to confirm these preliminary results. In order for such trials to recruit the required sample 
size, they will likely need to screen 5 times the number of participants needed.  
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Insomnia and issues with attention, memory and concentration are common among survivors of 
breast cancer. Although there are currently effective treatments for insomnia, very few, if any, 
treatments are effective for improving reports of attention, memory and concentration 
difficulties. This study evaluated how common these symptoms were together in survivors of 
breast cancer. Additionally, we determined if survivors of breast cancer were accepting of using 
the primary treatment for insomnia Cognitive Behavioural Therapy for Insomnia (CBT-I) to 
potentially improve complaints of attention, memory and concentration. We recruited 10 female 
survivors of breast cancer who resided in St. John’s, Newfoundland. Participants underwent 7 
weekly sessions of CBT-I treatment and completed questionnaires to assess attention, memory, 
concentration, sleep, and mood at baseline, 2 months (post-treatment), and 3- and 6-months 
following treatment, for a total study time of 8 months. Out of 45 participants screened, 10 had 
insomnia and issues with attention, memory and concentration. This means 22% of cancer 
survivors interviewed, displayed both insomnia and issues in these areas. CBT-I was highly 
accepted with 100% of enrolled participants completing the full treatment. There were 
significant improvements in self-reports of attention, memory and concentration, insomnia, 
fatigue, and depression over the 8-month study period. These improvements were maintained 
after treatment. CBT-I seems to be an acceptable and potentially effective option for improving 
reports of issues with attention, memory and concentration in survivors of breast cancer, but 
future studies are needed to confirm these results.   
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Exploring the Feasibility of Cognitive Behavioural Therapy for Insomnia on Perceived 
Cognitive Impairment in Survivors of Breast Cancer 
 Breast cancer is one of the most commonly diagnosed malignancies in Canada with 1 in 8 
women developing it in their lifetime (Canadian Cancer Statistics Advisory Committee, 2019). 
In 2019, breast cancer contributed to 25% of diagnosed cases of cancer in Canada (Canadian 
Cancer Statistics Advisory Committee, 2019). This is troublesome as Newfoundland and 
Labradorean women have one of the highest incidence and mortality rates for breast cancer 
across the country (Canadian Cancer Statistics Advisory Committee, 2019). Although prevalent, 
mortality due to breast cancer has decreased dramatically over the last three decades. In North 
America, breast cancer mortality has decreased by 34% with a more substantial decrease noted in 
Canada (48%; Canadian Cancer Statistics Advisory Committee, 2019). Predictions suggest that 
there will be a further 10% decrease in mortality from 2012 to 2020 (Carioli et al., 2018; 
DeSantis et al., 2014). Such decreases in breast cancer mortality can be attributed to improved 
management of the disease, earlier diagnosis, and advances in treatment (Carioli et al, 2018). 
Although a decrease in mortality rate is positive, many survivors of breast cancer struggle to 
resume normal functioning following treatment. Common long-term side effects include 
cognitive impairment (Janelsins et al., 2014), changes in mood (Carreira et al., 2018), and fatigue 
(Bardwell & Ancoli-Israel, 2008) that can individually and cumulatively have a negative impact 
on a patient’s quality of life (Argyriou et al., 2011). All of these symptoms have been associated 
with insomnia (Dirksen & Epstein, 2008; Fortier-Brochu et al., 2012). This study evaluated the 
feasibility and acceptability of using a psychosocial intervention designed to treat insomnia to 
improve associated symptoms in survivors of breast cancer. 
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Cognitive Impairment in Breast Cancer  
Based on neuropsychological assessments, approximately 30% of women with breast 
cancer report a decline in a variety of cognitive domains prior to treatment, while up to 75% 
report cancer-related cognitive impairments during their treatments (Janelsins et al., 2014). 
Furthermore, up to 35% of these women continue to experience cognitive difficulties for months 
or years following their treatments (Janelsins et al., 2014). A number of potential factors have 
been suggested to contribute to the cognitive impairment experienced by women with breast 
cancer including biological factors related to the disease (e.g., increased cytokine levels; 
Korkaya et al., 2011), physical effects of cancer treatments (e.g., chemotherapy, radiotherapy, 
and endocrine therapy; Ahles & Saykin, 2007; Janelsins et al., 2014), the psychological burden 
of the disease (e.g., anxiety, depression, fatigue and disrupted sleep; Argyriou et al., 2011; 
Bedillion et al., 2019), as well as life disruptions due to treatment (e.g., ability to return to work; 
Bradley et al., 2004; Myers, 2012). This literature review will focus on the factors associated 
cognitive impairment with the most empirical investigation to date: the effects of cancer 
treatments and the psychological burden of cancer.  
Cancer Diagnosis and Cognitive Impairment 
Prior to 2004 when prospective and longitudinal studies started to emerge, it was believed 
that chemotherapy was the sole contributor to cognitive decline in those with cancer (Hermelink, 
2015). Wieneke and Dienst (1995) conducted a cross-sectional study in 28 women with breast 
cancer to assess the effects of chemotherapy on cognitive functioning using a battery of 
neuropsychological tests. Although approximately 75% scored within the moderately impaired 
range on one or more of the test measures, these studies were not prospective and only looked at 
the effects of chemotherapy on women with breast cancer who had already undergone treatment 
and failed to measure cognitive impairment prior to the initiation of treatment. More recently, a 
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prospective, multicenter longitudinal study assessed the cognitive functioning of women with 
breast cancer prior to chemotherapy and found that about one-third experience pre-existing 
cognitive deficits prior to treatment (Hermelink et al., 2007). Therefore, without taking into 
account cognitive functioning prior to treatment, pre-existing cognitive impairments may have 
been misattributed to the effects of chemotherapy in the past literature. These findings suggest 
that the diagnosis as well as the neurotoxic effects of treatment seem to have implications on 
cognitive functioning within this population (Hermelink, 2015).  
Chemotherapy and Cognitive Impairment 
In women with breast cancer, chemotherapy-induced cognitive impairment—commonly 
referred to as “chemo brain”—is a common but under-recognized side effect (Argyriou et al., 
2011). Estimates suggest that 16-75% of women with breast cancer who receive standard to high 
doses of chemotherapy will report some level of cognitive dysfunction (Tchen et al, 2003; 
Wieneke & Dienst, 1995). Meta-analyses of neuropsychological studies have found only small 
differences in verbal ability and visuospatial ability domains following standard chemotherapy 
regimens in women with breast cancer compared to controls and pre-chemotherapy baselines 
(Jim et al., 2012). However, a more recent meta-analysis of 27 studies and a total of 81 
independent neuropsychological measures compared 1562 women with breast cancer who had 
undergone adjuvant chemotherapy treatment to 2799 controls consisting of women with breast 
cancer who did not receive adjuvant chemotherapy and healthy participants (Ono et al., 2015). 
Despite using differing methodological approaches, the results demonstrated consistent 
associations between adjuvant chemotherapy and cognitive impairment in a variety of domains 
including attention, executive function, information processing speed, motor function/speed, 
language, visuospatial ability/skill, short-term memory and long-term memory (Ono et al., 2015). 
Although these results are conflicting with regard to the exact cognitive processes chemotherapy 
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affects, it seems that memory, processing speed, and executive function are the most cognitively 
vulnerable, and are the processes most agreed upon within the literature (Correa & Ahles, 2008; 
Wefel et al., 2011; Wefel et al., 2008).  
A plausible explanation for the differing results on the cognitive processes affected by 
chemotherapy could be attributed to differing types of breast cancer, which require varying 
degrees of chemotherapy treatment. Those in different stages of breast cancer display various 
tumour subtypes and require differing intensities and durations of chemotherapy treatments 
(Seah et al., 2014). A significant negative relationship is present between the duration of 
treatment and cognitive functioning and this relationship seems to be dose dependent (Hodgson 
et al., 2012). Those undergoing longer and more intense chemotherapy treatments seem to be at 
an increased risk for deterioration in cognitive functioning. Van Dam and colleagues (1998) 
examined the level of cognitive impairment associated with varying dosages of adjuvant 
chemotherapy in breast cancer patients. Patients treated with high-dose chemotherapy appeared 
to be at an 8.2 times heightened risk of developing cognitive impairment compared to healthy 
controls. Furthermore, those who had undergone a higher dosage experienced more adverse 
cognitive functioning consequences (34%) compared to patients who had taken standard doses 
(17%). Further supporting the neurotoxic effects of chemotherapy on cognitive processes, 
women with breast cancer who had completed chemotherapy at least one-year prior show less 
cognitive deficits compared to those who were currently undergoing adjuvant chemotherapy 
(Brezden et al., 2000). Therefore, based on the current literature, it seems that cancer treatments 
may contribute to impairments in cognitive functioning and this relationship is dependent on 
factors such as cancer type and the associated duration and dosage of treatments. 
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Hormonal Therapies and Cognitive Impairment 
In addition to chemotherapy, hormonal therapies also appear to have a negative impact on 
cognitive functioning, particularly for women with breast cancer. Jenkins et al. (2006) examined 
this relationship in a prospective study and found that after 6 months following chemotherapy 
treatment, women with breast cancer who had experienced treatment-induced menopause were 
2.6 times more likely to show a decline in cognitive impairment compared to the postmenopausal 
women. There is evidence that deficits in attention, memory and concentration appear when 
women are deprived of estrogen earlier than normal due to ovarian suppression following 
chemotherapy and hormonal therapy (Bender et al., 2001). Estrogen is one of the female 
reproductive hormones that has neurological protective effects and increases synaptogenesis in 
brain regions important for memory (Yaffe et al., 1998). Therefore, hormonal restriction 
therapies that decrease these reproductive hormones may be contributing to the cognitive deficits 
seen within this population (Bender et al., 2001). Further evidence of this relationship is apparent 
through improved scores of learning and memory in postmenopausal women who are undergoing 
hormonal replacement therapy to counteract the negative effects of reproductive hormone 
deprivation (Henderson et al., 1994; Robinson et al., 1994). Evidence also suggests that the 
cognitive impairment experienced by women with breast cancer may not always persist. Out of 
50% of breast cancer survivors displaying cognitive dysfunction following chemotherapy, 
approximately 25% taking anti-estrogen hormonal therapies such as tamoxifen show 
improvements in cognitive dysfunction 2 years following chemotherapy treatment (Fan et al., 
2005). A possible explanation for these improvements during hormonal therapies may be 
attributed to neuroplasticity occurring following invasive treatments. Unfortunately, 25% of 
these women taking anti-estrogen hormonal therapies still show signs of at least mild cognitive 
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impairment (Fan et al., 2005) suggesting neuroplasticity following invasive cancer treatments 
may not be enough to restore cognitive processes.  
Perceived Cognitive Impairment in Breast Cancer 
The relationship between cognitive impairment and breast cancer appears to be stronger 
when assessed with subjective self-report measures of cognitive function compared to objective 
assessments (Ono et al., 2015; Hodgson et al., 2012; Hutchinson et al., 2012; Jean-Pierre et al., 
2014). Due to the inconsistency regarding the cognitive domains that seem to be affected by 
chemotherapy using objective cognitive measures, researchers have suggested that “chemo 
brain” may largely be a subjective experience (Hermelink, 2015). While this may lead some to 
dismiss or minimize its significance, Savard and Ganz (2016) have suggested that the subjective 
experience of cognitive impairment is as, or more, important than an objective classification. 
Investigating the emotional component of cognitive decline is important as 50% of cancer 
survivors experience perceived cognitive impairment (PCI) and report it is one of the largest 
barriers to resume normal functioning (Boykoff et al., 2009; Janelsins et al., 2014; Schmidt et al., 
2016). It is also arguable that an individual’s perception of their cognitive impairment is essential 
when trying to measure the impact of interventions that focus on improvements in quality of life 
(Basch, 2016). Subjective perceptions, which can be reliably measured using validated 
instruments, allow us to observe the impact that declines in cognitive performance have on an 
individual’s daily functioning (Basch, 2016). With such valuable information, it may be more 
meaningful to target how the patient feels about their cognitive performance rather than just 
objective measurements, which fail to assess the emotional component of cognitive impairments. 
Such cognitive complaints are associated with a variety of additional symptoms such as 
decreased quality of life, daily functioning impairment, emotional distress, fatigue, psychological 
distress and stress (Argyriou et al., 2011; Bedillion et al., 2019; Boykoff et al., 2009; Hutchinson 
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et al., 2012; Moon et al., 2011). PCI can also negatively impair performance at work or ability to 
return to work (Boykoff et al., 2009; Munir et al., 2010). This can cause prolonged leaves of 
absence or early onset retirement which has significant consequences for both the individual and 
society (Boykoff et al., 2009; Munir et al., 2010).  
Treatment for Perceived Cognitive Impairment 
Although PCI seems to be highly prevalent in cancer patients, there are few effective 
treatments (Jean-Pierre et al., 2014; Joly et al., 2015). Cognitive rehabilitation programs and 
physical exercise/mental stimulation are the most common intervention strategies. Based on a 
methodological review, cognitive interventions have reported some benefits for attention, 
memory, functional communication, and executive functioning, but they can vary substantially 
based on the technique used (Jean-Pierre et al., 2014; Kesler et al., 2013). Cognitive 
rehabilitation programs aim to reduce cognitive dysfunction and improve quality of life through 
psycho-education and cognitive-behavioural strategies. One feasibility study found 
improvements in overall cognitive function, perceived cognitive function, social functioning, and 
decreased levels of psychological distress in survivor of cancer populations which were 
maintained for three months following cognitive rehabilitation treatment (Schuurs & Green, 
2013). However, this study lacked statistical power, failed to randomly assign participants to 
groups, and also had a larger number of cancer survivors in their intervention group. As such, the 
treatment effects could have been inflated and the effectiveness of cognitive rehabilitation within 
this population requires further investigation.  
Physical exercise/mental stimulation to improve cognitive impairment has also been 
investigated. A randomized controlled trial of 81 women with breast cancer evaluated the 
effectiveness of exercise and meditation on subjective cognitive function (Oh et al., 2011).  
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Although significant improvements were noted in perceived cognitive impairment, the mean 
difference out of a 5-point scale was slight (MD= 4.70) and would not constitute a clinically 
meaningful change of 5.9 (Bell et al., 2018). This study also did not follow up on their 
participants to ensure treatment effects were maintained and therefore, the effectiveness of this 
intervention remains inconclusive. 
In addition to cognitive and physical activity interventions, medications such as 
modafinil, methylphenidate, gingko biloba, and donepezil + vitamin E have been investigated. 
Methylphenidate (Ritalin) is a pharmaceutical commonly used to treat attention-deficit 
hyperactive disorder, narcolepsy, and cognitive decline in patients with brain tumors. However, a 
double-blind, placebo-controlled trial of 57 women with breast cancer undergoing adjuvant 
chemotherapy found no significant differences on objective or subjective cognitive impairment 
in those who had taken 5-10 mg twice daily of methylphenidate over the course of treatment 
compared to placebo (Mar Fan et al., 2008). Overall, methylphenidate seems to alleviate cancer-
related fatigue but has no effect on chemotherapy-induced cognitive impairment (Argyriou et al., 
2011; Minton et al., 2010). Based on double-blind randomized controlled trials, gingko biloba 
and donepezil, which are used to treat cognitive impairment in other chronic disease populations, 
are ineffective as well (Barton et al., 2013; Jatoi et al., 2005). Preliminary evidence from a 
randomized controlled trial suggests that modafinil may be beneficial in improving cognitive 
functioning in women with breast cancer following chemotherapy (Kohli et al., 2009), although 
these effects have not been consistent across studies (Davis et al., 2013).  Overall, medications 
for reducing cognitive impairment in survivors of breast cancer have not demonstrated much 
promise (Argyriou et al., 2011; Hines et al., 2014; Joly et al., 2015). 
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Although cognitive, behavioural, and pharmaceutical treatments have been investigated 
for the treatment of PCI in individuals with cancer, no one treatment has emerged as an agreed 
upon standard. As such, we need to continue to examine other potential treatment options that 
take into account factors that may be contributing to PCI such as sleep, fatigue, and mood 
disturbance.  
Protective Effect of Sleep on Cognitive Impairment 
Sleep plays an important role in neuroplasticity and allows us to repair and restore the 
micro injuries that occur in our brain on a daily basis (Karren et al., 2013). The benefits of sleep 
on neuroplasticity can be observed while examining sleep-deprived individuals. Over 50% of 
those diagnosed with a sleep disorder that prevents REM sleep (REM Behaviour Disorder) have 
been found to later develop dementia or Parkinson disease, demonstrating the therapeutic 
properties of sleep on cognition (Postuma et al., 2010). Similarly, sleep deprivation is a common 
symptom in about 50% of clinical and community-based samples of Alzheimer’s disease and has 
been linked to memory deficits within this population (Qiu et al., 2009; Vitiello & Borson, 2001; 
Walker, 2017). This relationship is further supported by animal models that have restrained rats 
to four hours of sleep per night for eight weeks and found a significant decline in their learning 
and memory tasks compared to controls (Dimeco et al., 2014). Sleep also allows us to integrate 
our experiences by organizing memories and incorporating the day’s experience into our 
worldview during a restful state (Karren et al., 2013). Poor sleep quality in humans has negative 
impacts on a variety of additional cognitive functions such as attention, memory, executive 
function, and behavioural alertness (Banks & Dinges, 2007), cognitive issues which are similarly 
reported in women with breast cancer (Argyriou et al., 2011; Hines et al., 2014). These results 
are quite troublesome as one of the most frequent reasons survivors of cancer visit their general 
practitioner is due to sleep difficulties (Heins et al., 2013). Although it has yet to be empirically 
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demonstrated, good sleep may act as a protective agent against the neurotoxic effects of cancer 
treatments on cognitive functioning in women with breast cancer.  
Insomnia in Breast Cancer 
 Insomnia is defined as difficulty falling and/or staying asleep more than three nights a 
week and ongoing for at least 3 months despite adequate opportunity for sleep (American 
Psychiatric Association, 2013). In order to be categorized as a disorder, the presented sleep 
issues must cause distress and significantly impact daily functioning. Insomnia is a prevalent and 
frequently overlooked experience associated with breast cancer onset and treatment (Palesh et 
al., 2013; Savard & Savard, 2013). Women with breast cancer have a significantly higher risk 
(between 42-69%) for developing insomnia compared to adults with other cancer types (Heins et 
al., 2013; Savard et al., 2011). Large-scale epidemiological studies demonstrate that 
approximately 60% of women treated for breast cancer experience insomnia, which can persist 
for years if not treated appropriately (Palesh et al., 2010; Savard et al., 2011). A variety of 
hypotheses have been proposed regarding the association between insomnia and cancer including 
biological factors such as treatment-induced circadian disruption, psychological factors such as 
depression, and treatment side effects such as hot flashes (Desai et al., 2013; Liu et al., 2013; 
Savard et al., 2009; Stepanski et al., 2009). Although no one cause has been determined, most 
patients report that their insomnia either began with or shortly followed their diagnosis, 
suggesting that poor sleep is more overwhelming than the cancer treatments themselves (Fleming 
et al., 2010). Insomnia negatively impacts work performance for survivors of cancer, 
corresponding to 7.8 fewer workdays and a loss on average of $2,280 in income per person per 
annum (Kessler et al., 2011). Therefore, not only is PCI associated with burdens to both the 
individual and society, but insomnia shows a similar association as well. Although it is apparent 
a relationship is present between cognitive impairment and insomnia in women with breast 
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cancer, the relationship has not been well studied and research is lacking on validated treatment 
options for both.  
Treatment Options for Insomnia 
 Current treatment options for insomnia include both behavioural and pharmaceutical 
based therapies. In the United States, 11 pharmaceuticals have been approved to treat insomnia, 
although none of these have been specifically tested for efficacy and safety in those with cancer 
(Fiorentino et al., 2011). Although pharmaceutical treatments have been found to improve sleep 
onset, many patients report large tolerance effects and poor quality of sleep, as well as increased 
severity of insomnia, fatigue, and pain from cessation. Therefore, behavioural therapies are 
frequently preferred due to much lower side effects. 
Cognitive Behavioural Therapy for Insomnia. Cognitive Behaviour Therapy for 
Insomnia (CBT-I) is recommended by the American Academy of Sleep Medicine as the primary 
treatment for chronic insomnia (Boykoff et al., 2009; Joly et al., 2015). CBT-I has consistently 
been found to be more effective in treating insomnia both in the short and long term when 
compared to sleep aids such as benzodiazepines (Mitchell et al., 2012). CBT-I is a multi-
component weekly intervention that combines principles from stimulus control and sleep 
restriction with formal cognitive restructuring in order to target hyper-arousal, dysfunctional 
behaviours, and maladaptive thoughts, beliefs and attitudes associated with insomnia. The five 
main components of CBT-I are: sleep restriction, stimulus control, cognitive restructuring, 
relaxation training, and sleep hygiene. Sleep restriction promotes consolidation of sleep periods 
through a build-up of sleep drive by restricting the time spent in bed as close as possible to the 
time actually spent sleeping. A sleep efficiency percentage is then calculated (amount of time 
spent sleeping divided by the amount of time in bed). When an individual achieves 85% sleep 
efficiency, their prescribed time in bed is increased. This continues until the patient can achieve 
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adequate sleep quantity and quality with little to no disturbances. Stimulus control is designed to 
condition the body to associate the bed with sleepiness and to avoid the association of the bed 
with wakefulness. This technique is aimed at breaking perpetuating behaviours that contribute to 
insomnia such as going to bed too early and “trying’ to sleep. Cognitive restructuring addresses 
dysfunctional beliefs and thoughts that maintain and exacerbate behaviors which perpetuate 
insomnia symptoms. With the assistance of the therapist, the patient monitors these thoughts and 
beliefs, assesses their validity, and if necessary, replaces them with accurate and/or less 
distressing cognitions advantageous to the sleep process. Lastly, relaxation training targets 
cognitive and physiological arousal that exacerbates insomnia and sleep hygiene promotes ideal 
sleep behaviours and environmental conditions.  
A systematic review and meta-analysis of the efficacy of CBT-I in cancer patients found 
significant improvements indicated by moderate to large effect sizes (Cohen’s d) in sleep 
efficiency (d = 0.53), sleep latency (d = 0.43), and amount of time awake during the night (d = 
0.41). Significant improvements were also present in insomnia severity indicated by a large 
effect size (d = 0.77) and these effects were maintained for up to 6 months (Johnson et al., 2016). 
Importantly, the effects of CBT-I were noted across differing delivery modalities (individual, 
group, online and video), durations of the intervention, as well as a variety of cancer 
diagnoses/stages. This indicates that CBT-I not only produces significant and durable changes in 
insomnia severity but also is effective in reducing insomnia symptoms in a heterogeneous 
sample of cancer patients. 
Fatigue in Breast Cancer 
 In addition to insomnia, approximately 33% of women with breast cancer will experience 
persistent fatigue, which can continue into their survivorship for up to 10 years if not treated 
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appropriately (Bardwell & Ancoli-Israel, 2008). Cancer-related fatigue differs from daytime 
sleepiness and is described as ‘...a subjective state of overwhelming and sustained exhaustion 
and decreased capacity for physical and mental work that is not relieved by rest.’ (Cella et al., 
1998, p. 369). Cancer-related fatigue often appears as a cluster of symptoms with insomnia, pain 
and depression making it an important symptom to take into consideration when targeting 
symptoms that often co-occur (Bardwell & Ancoli-Israel, 2008; Donovan & Jacobsen, 2007). 
Fatigue related to cancer is often present with subjective cognitive complaints in survivors of 
breast cancer as well. Li and colleagues (2015) conducted a cross-sectional observational study 
on 204 women with breast cancer to examine the effect of psychological functioning on PCI 
following chemotherapy. It was found that Post Traumatic Stress Disorder symptoms and fatigue 
independently accounted for PCI while controlling for age, education, anxiety and depression. 
Possible explanations for the association between fatigue and PCI may be due to the neurological 
implications of invasive treatments. Robust evidence suggests inflammatory processes are 
triggered and/or worsened by the cancer treatments and therefore can lead to symptoms of both 
fatigue and cognitive dysfunction (Joly et al., 2019). These findings support the need to account 
for not only insomnia when trying to improve subjective cognitive complaints but cancer-related 
fatigue as well. 
Mood Disturbance in Breast Cancer 
  Similarly, to insomnia and fatigue, psychological functioning is often impacted following 
the stressful news of a cancer diagnosis (Palesh et al., 2013). A population-based 
epidemiological study of 53,258 found that women with breast cancer are at a 1.33 heightened 
risk of reporting levels of mood disturbance including an increased risk of anxiety, depression 
and suicide compared to a matched control cohort (Carreira et al., 2018; Hung et al., 2013). 
Hartung and colleagues (2017) examined the prevalence of depression in a multi-center 
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epidemiological study and reported those with cancer are five times more likely to display 
depressive symptoms compared to the general population. Depression has been identified as the 
most common mood disturbance symptom in women with breast cancer, although anxiety 
symptoms are prevalent as well (Fiorentino et al., 2011). Based on clinical questionnaires, the 
prevalence of anxiety and depression in women with breast cancer is 19% and 17%, respectively 
(Lueboonthavatchai, 2007). A longitudinal study of 222 women with breast cancer found that 
women were most vulnerable within the first three months after a diagnosis, with about half of 
those with breast cancer having at least one period of anxiety and depression within this time 
frame (Burgess et al., 2005).  
Mood Disturbance and Insomnia 
Mood disturbance is also associated with insomnia in women with breast cancer, with 
both often co-occurring, exacerbating the other, and affecting the patient’s quality of life 
(Fiorentino et al., 2011; Redeker et al., 2000). A meta-analysis of 16 studies investigated the 
relationship between depression and insomnia in those with cancer who were undergoing mixed 
treatment modalities (Donovan & Jacobsen, 2007). A moderate correlation was observed 
between insomnia and depression (r = .45). Fatigue also seemed to be influencing this 
relationship with significant associations between insomnia and fatigue (r = .34) and depression 
and fatigue (r = .55). Although there is an abundance of support for the relationship between 
insomnia and anxiety symptoms, very little research has been conducted on this interaction 
within breast cancer patients. Most reports include the more generalized term mood disturbance, 
which includes depression as well. Regardless, the relationship between insomnia and mood 
disturbance is of particular concern for this population as a bidirectional relationship seems to be 
present, with each negatively affecting the other (Glidewell et al., 2015). As a result, women 
with breast cancer who experience one of these symptoms are at a heightened risk for the other 
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as well. Examining clusters of symptoms experienced by breast cancer survivors such as anxiety, 
depression, fatigue, and insomnia are important to take into consideration as they may provide 
evidence to why treatment modalities to treat cognitive impairments have been previously 
unsuccessful. 
Mood Disturbance and PCI  
Hutchinson et al. (2012) proposed that the differences in objective and subjective 
cognitive impairment are due, in part, to the influence of psychological distress. Subjective 
cognitive complaints have been consistently correlated with varying measures of psychological 
distress including depression and anxiety symptoms (Hutchinson et al., 2012). Bedillion and 
colleagues (2019) examined whether depression mediated the effect of cancer treatment on PCI 
in survivors of breast cancer in a cross-sectional survey of 317 patients who had received all 
adjuvant treatments less than 10 years prior. Women completed self-report questionnaires 
examining PCI, depressive symptomology, and physical activity. Depression partially mediated 
the relationship between the effects of treatment on PCI, indicating that depression was partially 
contributing to participants’ PCI following treatment. In addition, physical activity acted as a 
moderator on this relationship with increases in physical activity being correlated with lower 
depressive symptomology and therefore lower PCI. Therefore, it appears the effect of depression 
needs to be taken into consideration when examining treatment options for PCI as improvements 
in one may yield improvements in the other.  
In addition to depression, Moon and colleagues (2011) examined whether PCI was 
related to general mood disturbance in a cross-sectional survey of 118 women with breast cancer 
who had either undergone or were currently undergoing chemotherapy. Using self-report 
questionnaires, mood disturbance was significantly associated with PCI, with those who had 
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higher scores of mood disturbance reporting higher levels of PCI. With such findings, a strong 
relationship seems apparent between psychological distress and PCI. Therefore, in addition to 
depression, anxiety should also be taken into consideration when investigating treatment 
modalities to improve PCI to capture differing measurements of mood disturbance.  
Treatment of Cognitive Impairment, Insomnia, Fatigue and Mood Disturbance 
Based on the presented evidence, cognitive impairments in breast cancer survivors cannot 
be associated to a singular cause (See Figure 1, pg. 69). Rather, there seem to be interactions 
among the cancer treatments (e.g., chemotherapy, hormonal restriction therapies), psychological 
side effects of these treatments (e.g., depression, anxiety, and fatigue), sleep disturbance 
associated with treatments that can develop into insomnia, as well as physical side effects of the 
treatments (e.g., hot flashes, pain, and fatigue). All of these taken together can lead to the 
development and maintenance of cognitive impairments and are therefore important to consider 
when investigating effective treatment options. Current research shows that in addition to 
insomnia, CBT-I can also reduce clinical levels of fatigue, anxiety, and depression related to 
cancer treatments (Fleming et al., 2014). Due to the high co-occurrence of psychological distress 
and insomnia, many treatment programs designed to decrease one tend to have a positive 
influence on the other symptoms as well (Dirksen & Epstein, 2008; Kim et al., 2018). CBT-I in 
particular has been found to be an effective treatment for improving levels of psychological 
distress compared to other treatment options. Garland and colleagues (2014) evaluated the 
effectiveness of both CBT-I and Mindfulness-Based Stress Reduction (MBSR) therapy on 
improving insomnia, mood and stress symptoms in cancer survivors. Using a partially blinded, 
randomized trial with 111 survivors of cancer experiencing insomnia, they found both MBSR 
and CBT-I significantly improved insomnia severity, stress level and mood disturbance although, 
the effects of CBT-I were more rapid and durable over time.  
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Preliminary research suggests that CBT-I may also improve PCI in individuals without 
cancer. A systematic review of 18 studies investigating the impact of CBT-I on cognitive 
functioning in those with insomnia and found small to moderate effects of CBT-I in treating 
subjective cognitive impairment (Herbert et al., 2018). Although these results are promising, they 
were not conducted in survivors of cancer and require additional research using subjective and 
objective measures of cognitive functioning, and controlling for confounding variables (Hines et 
al., 2014). In summary, insomnia, mood disturbance, and cancer treatments have been associated 
with PCI, putting survivors of cancer experiencing insomnia symptoms at an increased risk for 
the of development of PCI and making research on the treatment of insomnia in cancer survivors 
a priority for clinicians, researchers, and patients (Vardy et al., 2008). 
Objectives of the Current Study 
The current study will assess the feasibility, acceptability, and preliminary effectiveness 
of using the ‘gold standard’ non-pharmacological intervention for insomnia (CBT-I) to improve 
PCI in survivors of breast cancer. This will allow us to determine the feasibility for subsequent 
randomized controlled trials. To inform future research, we will use both subjective and 
objective measures of cognitive impairment as well as examine co-morbid symptomology. 
Should the intervention be feasible and acceptable, it could open up new treatment possibilities 
for PCI, a condition with few effective treatment options. In addition, this therapy could 
potentially improve a cluster of psychological symptoms associated with breast cancer 
treatments therefore providing a more cost-effective treatment for the patient. Lastly, an effective 
intervention would provide justification and important pilot data for larger randomized 
controlled trials. The specific objectives of this study are: 
1. Estimate the feasibility of recruitment of survivors of breast cancer who report both 
insomnia and cognitive impairments. 
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2. Collect pilot data on the acceptability of the intervention and completion of the study 
protocol (including documentation of incomplete data and drop-outs). 
3. Estimate the effect of CBT-I on PCI and related symptoms (objective cognitive 
impairment, insomnia, sleep efficiency, fatigue, depression and anxiety) and assess 
whether any changes observed are durable up to 6 months post-treatment.  
Methods 
Participants 
Participants were deemed eligible if they: were diagnosed with stage I-III breast cancer; 
were English speaking; had received and completed all adjuvant treatments for non-metastatic 
breast cancer at least 12 months prior to study entry but no more than 5 years (continued 
maintenance or hormonal treatments were acceptable); reported dissatisfaction with their 
memory, concentration, and/or attention as indicated by a score of “quite a lot” or “always” on at 
least one of the two items used to assess concentration and memory (questions 20 and 25) on the 
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 
(QLQ-C30; Aaronson et al., 1993); met the DSM-5 criteria for insomnia disorder determined as 
difficulty falling and/or staying asleep more than three nights a week and ongoing for at least 3 
months despite adequate opportunity for sleep (American Psychiatric Association, 2013) and had 
a score >8 on the Insomnia Severity Index; and resided in the metro area of St. John’s, NL. 
Participants were excluded from the study if they had severe cognitive impairments as indicated 
by a score of < 23 on the Montreal Cognitive Assessment (MOCA; Nasreddine et al., 2005), 
another untreated sleep disorder such as obstructive sleep apnea, previous experience with CBT-
I, a major sensory deficit, a neurologic or major medical condition known to affect cognitive 
function, a history of inpatient psychiatric hospitalization, a history of cranial radiation, a change 
in psychotropic medications less than six weeks prior to study entry, an Eastern Cooperative 
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Oncology Group (ECOG) performance score greater than two (Oken et al., 1982) or a life 
expectancy of less than five years. 
Procedure 
The primary means of recruitment was through self-referral. Participants were made 
aware of the study through study information posted at the Dr. H. Bliss Murphy Cancer Centre 
and community organizations, referrals from medical professionals working for both the Cancer 
Centre and Eastern Health, information provided at community events directly related to targeted 
participants, and information posted through social media platforms. All interested participants 
were directed to our website for additional information and provided with an email and phone 
number to contact a research assistant to obtain additional details regarding the study. Interested 
participants underwent two screening processes. If those who were interested met all eligibility 
criteria that could be determined via a telephone interview, they were further screened in person. 
Those who were deemed eligible were enrolled in the study. Participants received 7 individual 
sessions of CBT-I with one individual therapist who oversaw all participants over the course of 8 
weeks. At the end of each treatment session, participants were given a sleep diary to complete for 
the following week that was reviewed and used by the therapist to tailor treatments. A detailed 
week-to-week description of the CBT-I protocol is provided in Appendix A (pg. 74). Participants 
also underwent assessments at five different time points by one single research assistant besides 
the therapist: baseline, mid-treatment (4 weeks), post treatment (8 weeks), a 3 month follow up 
and a 6 month follow up. See Figure 2 (pg. 70). The total study time was 12 hours over an 8-
month period for assessments and treatment. Ethical approval for this study was obtained from 
the Health Research Ethics Board of Memorial University (See Appendix B pg. 78) 




A medical history and demographics questionnaire developed for this study was used to 
obtain demographic information (e.g., sex, age, ethnic background, education, marital status, 
employment status), medical history (e.g., type of cancer, date of diagnosis, treatment details), 
psychiatric history and current medication use. Each assessment included measures of cognitive 
function, sleep, fatigue, anxiety and depression. 
Subjective Cognitive Function 
  The Functional Assessment of Cancer Therapy – Cognitive Function (FACT-Cog) 
version 3 is a 37 item self-report questionnaire that measures four different aspects of cognition 
in the past week: perceived cognitive impairments (PCI), impact on quality of life, comments 
from others and perceived cognitive abilities (Jacobs et al., 2007; Von Ah & Tallman, 2015).  
For the purposes of this study, the PCI subscale score of the FACT-Cog was used to capture 
subjective cognitive impairment (See Appendix C, p. 80). Responses to each question range from 
0 to 4 with 0 indicating “never” and 4 indicating “several times a day.” Negatively worded items 
are reverse scored to create subscale scores, with higher scores reflecting fewer cognitive 
problems and better quality of life. Scores on the PCI subscale range from 0 to 72. A change of 
5.9 points has been established as clinically meaningful change on the FACT-Cog PCI subscale 
(Bell et al., 2018). The FACT-Cog has been validated specifically for women with breast cancer 
and has been found to be a reliable measure with a Cronbach alpha of 0.86 for the total score, 
and the subscale scores ranging from 0.77 to 0.86 (Lai et al., 2009; Wagner et al., 2009). 
Objective Cognitive Function 
Verbal Learning and Memory: The Hopkins Verbal Learning Test-Revised (HVLT-R) is 
a brief assessment of verbal learning and memory, specifically immediate recall, delayed recall, 
and delayed recognition (Brandt, 1991). Each form consists of 12 nouns, with four words drawn 
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from three semantic categories and requires participants to recall the words read aloud by a 
trained assessor. Four different forms were used at each of the assessment time points. For the 
purpose of this study, delayed recall scores presented as a recall percentage were used to 
determine cognitive functioning in verbal learning and memory. The HVLT-R has six alternative 
forms making it suitable for repeated testing (Brandt & Benedict, 2001), has high test-retest 
reliability and has been well established with regards to its construct, concurrent and 
discriminant validity.  
Verbal Fluency and Executive Functioning: The Controlled Oral Word Association Test 
(COWAT) is a measure of verbal fluency, cognitive and motor speed, and executive functioning 
performance such as cognitive flexibility, strategy utilization, interference suppression, and 
response inhibition (Lezak et al., 2004). The test requires participants to say as many words they 
can think of as quickly as they can that begin with a certain letter of the alphabet (avoiding 
proper nouns and words with different suffix) in a one-minute interval. Scores are adjusted based 
on age and education. For the purpose of this study, adjusted scores were used to determine 
change in cognitive functioning. The COWAT has two alternative forms which were used at 
baseline and 6 months, making it suitable for a repeated testing. Results are compared against 
normative data. 
Divided Attention and Processing Speed: The Colour Trails Test (CTT) is a widely used 
measure of executive function (D’Elia et al., 1996; Maj et al., 1993) Successful performance 
requires a wide range of mental abilities such as mental flexibility, visual scanning, and motor 
function. The test has two forms, one where participants are required to work as quickly as they 
can to connect numbered circles in order and another that does the same but switches the colour 
of the circles each time. The second form is a measure of divided attention and processing speed 
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and the completion time in seconds was used to calculate change in cognitive functioning in this 
study. It has the same sensitivity and specificity as the original Trail Making Test and presents 
age- and education- corrected normative data collected from a sample size of 1528 participants 
(Lezak et al., 2004). The CTT has four alternative forms which were used during each 
assessment making it suitable for repeated testing. It has demonstrated adequate test-retest 
reliability and has excellent concurrent validity with the original Trail Making Test (D’Elia et al., 
1996; Elkin-Frankston et al., 2007). 
Insomnia and Sleep Continuity  
The Insomnia Severity Index (ISI) is a self-report measure that consists of 7 items 
designed to assess the severity of insomnia symptoms, the impact on daytime functioning, and 
the amount of associated distress within the last two weeks (See Appendix D, p. 82; Bastien et 
al., 2001). Items are scored on a Likert-scale of 0-4, with the highest possible score of 28. Scores 
of 0-7 are classified as no clinically significant insomnia, 8-14 as sub-threshold insomnia, 15-21 
as clinical insomnia of moderate severity, and 22-28 as severe clinical insomnia. A change of 8.4 
points has been established as clinically meaningful change on the ISI (Morin et al., 2011). The 
ISI has demonstrated internal consistency, reliability, construct validity, specificity and 
sensitivity in a representative sample of 1670 individuals living with cancer (Savard et al., 2005).  
The Consensus Sleep Diary (CSD) is a self-report measure of sleep pattern and quality 
for each night for 7 consecutive days (Carney et al., 2012). The CSD was used to record nightly 
sleep-onset latency, wake after sleep onset, total sleep time, time in bed, number of awakenings, 
sleep quality and terminal wakefulness, which was then averaged over the 7 days. As a summary 
score, sleep efficiency percentages were calculated by dividing the amount of time spent in bed 
for the week by the amount of time actually spent sleeping for the week multiplied by 100% to 
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gain a percentage score. A sleep efficiency of above 85% is considered good. Sleep diaries are a 
reliable and valid self-report of nightly insomnia symptoms (Maich et al., 2016). 
Sleep-wake activity was monitored using an actigraph, which is a watch that participants 
wear for 7 consecutive days. The actigraph monitors movement using an accelerometer to assess 
sleep-wake cycles by measuring sleep efficiency, sleep latency, total sleep time, and number and 
frequency of awakenings (Vallieres & Morin, 2003). To allow for comparison with sleep diaries, 
we used sleep efficiency percentages as a summary variable. The Micro Motionlogger brand has 
a 95% sensitivity, a 65% specificity, and a 90% agreement with polysomnographic data (Rupp & 
Balkin, 2011). 
Fatigue 
The Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) is a 30 item 
self-report measure of the physical and psychological aspects of fatigue on 5 subscales (general, 
emotional, physical, mental and vigor) and a total fatigue score (Stein et al., 2004). The MFSI-SF 
reports symptoms of fatigue for a one-week period. For the purposes of this study, the total 
fatigue score was used. The total MFSI-SF score range from -24 to 96 with larger scores 
indicating more fatigue. A minimal clinically important difference has been identified as 10.79 
for the MFSI-SF (Chan et al., 2018). The MFSI-SF has been validated in a sample of cancer 
patients compared to a healthy population (Stein et al., 2004) and has an internal consistency 
based on Cronbach alpha of 0.87 for the total score in breast cancer patients (Donovan et al., 
2015;  
Mood Disturbance 
 The Hospital Anxiety and Depression Scale (HADS) is a self-rated instrument with 14 
items and two subscales: one for depressive symptomology and one for anxiety symptomology 
in the past week (Bjelland et al., 2002). Each item is scored from 0 to 3 and totalled. Established 
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cutoffs are: 0–7 not significant; 8–10 subclinical; and 11-21 clinically significant 
depression/anxiety. A minimal important difference for the HADS anxiety and depression scores 
has been determined as 1.3 and 1.4 points, respectively (Puhan et al., 2008). The HADS has been 
validated and used extensively in individuals with cancer showing reliability, specificity and 
sensitivity (Uchino et al., 2011). Cronbach's alpha of the HADS-A and HADS-D sub-scales in 
breast cancer patients are 0.79 and 0.87 respectively (Rodgers et al., 2015). 
Treatment Acceptability 
 The Credibility/Expectancy Questionnaire (CEQ) is a self-report 6-item measure that 
evaluates the participant’s perception of treatment effectiveness after the intervention has been 
described in detail prior to starting the treatment (Devilly & Borkovec, 2000). Items 1-3 and 5 
are measured on a 9-point Likert scale. Items 4 and 6 are measures on a percentage scale of 0-
100. The questions investigate how logical the treatment appears, how successful they think it 
will be, how likely they would be to recommend it to a friend, how much improvement they 
think they will make, how much they feel the treatment will improve symptoms, and how much 
improvement they feel will occur by the end of treatment. The scale is interpreted by creating an 
overall credibility factor (taking the mean of questions 1 to 3) and an expectancy factor (question 
4). For the purposes of this study we adjusted the questionnaire to specify how much 
improvement they think/feel they will make in regard to their insomnia and cognitive 
functioning. The CEQ has demonstrated high internal consistency within each factor and good 
test-retest reliability (Devilly & Borkovec, 2000). The expectancy factor single question 
maintains the high degree of face validity and is the most commonly used indicator of treatment 
outcome expectancy in psychotherapy and clinical trial research (Borkovec & Mathews, 1988; 
Borkovec et al., 2002; Constantino et al., 2011; Delsignore & Schnyder, 2007; Westra et al., 
2011) 




Participants met for their individualized sessions with a trained doctoral student therapist 
at the psychology clinic. To ensure treatment consistency, a single therapist administered all 
sessions. The therapist was trained and supervised by a clinical psychologist with extensive 
experience delivering the intervention and providing supervision. The training consisted of 
teaching from a manualized CBT-I protocol developed by the clinical psychologist o effectively 
deliver CBT-I in the context of cancer and other chronic conditions. The supervision involved 
weekly case meetings for audiotape review to ensure adherence to CBT-I protocol. Each 
treatment sessions lasted approximately one hour. See Appendix A (pg. 74) for daily intervention 
breakdown.  
Sample Size 
 The intended sample size was 30, which was estimated by a power calculation for pilot 
trials in clinical and translational research and based on previous studies with this patient 
population (Janelsins et al., 2014; Moore et al., 2011). It is recommended that single-arm clinical 
pilot studies aimed at testing the efficacy of an intervention that are being subsequently tested in 
larger trials to keep levels of type I error rates around 10–25% and type II error rates low (β ≤ 
10%). Our sample size estimate was based on our primary outcome of PCI using the FACT-Cog. 
A change of 5.9 points has been established as clinically meaningful change on the FACT-Cog 
PCI subscale (Bell et al., 2018). Based on the primary outcome being continuous, this trial was 
powered using a dependent samples t-test score at post-treatment. Using a beta of 0.90 and a 
two-sided alpha of 0.25, 25 participants were needed to detect an effect size of 0.5. Due to the 
pilot trial nature of this study, we adjusted for a potentially large attrition rate of 20% from 
previous studies, resulting in a desired sample of 30 participants. 




Questionnaires were filled out during each assessment and later entered into SPSS 
statistical software for future data analysis. Sleep diaries and actigraphs were collected one week 
following each assessment/treatment session and immediately downloaded and entered into 
SPSS. To minimize missing data, all surveys were checked upon completion. If missing data was 
identified the same day, participants were contacted via telephone to indicate unanswered 
questions. 
Quantitative Data Analysis 
Descriptive statistics were used to characterize the sample and are presented in Table 1 (pg. 
65). Due to the exploratory nature of the present research, and the problematic interpretation of p 
values in small samples, effect sizes of partial eta squared (0.01 small, 0.09 medium and 0.25 
large) were reported in addition to p values with significance level set at p < .05. Since this 
research is not aimed at hypothesis testing, no corrections were made for multiple comparisons. 
Data analysis was conducted in line with the study objectives: 
1. Feasibility of Recruitment- The feasibility of conducting a longitudinal study with 
survivors of breast cancer was assessed by: the number of patients screened as identified 
by a research assistant and the number who both consented and completed the baseline 
assessment package. Reason for patient ineligibility is also reported. 
2. Acceptability of Research Protocol and Intervention- Participants who consented and 
completed their baseline assessment were included in the final sample. Treatment 
acceptability was calculated using range of values (mean and standard deviation) for the 
CEQ. Completion rates were calculated based on the proportion of participants who 
completed the questionnaire packages at each time point. Reason for study withdrawal 
was indicated.  
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3. Treatment Effect and Durability - Range of values (mean and standard deviation) for all 
questionnaires was reported for the total scores at each time point. To investigate the 
impact of CBT-I treatment, a repeated measures analysis of variance (ANOVA) was 
performed for four assessment points (baseline, post-treatment, 3 month and 6 month 
follow-up) for each individual measure of cognition, insomnia, sleep, fatigue, and mood. 
Follow-up pairwise comparisons between data collection points were calculated to see 
where exactly the differences lay. Normative data based on age, sex and education 
demographics were used to examine objective cognitive function (Benedict et al., 1998; 
Loonstra et al., 2001; Ruff et al., 1996). 
Missing Data 
To determine the amount of existing missing data in our data set, a missing values 
analysis was conducted using SPSS. Due to the longitudinal data we were able to collect from 
participants, this method also imputed missing values with estimated values using estimated 
means methods to account for all missing data variables throughout the study. Multiple 
imputation methods were deemed unnecessary given the small sample size and low percentage 
of missing data.  
Results 
Objective 1: Feasibility of Recruitment 
The primary objective of this pilot study was to estimate the feasibility of recruiting 
women who have survived breast cancer who report both insomnia and cognitive impairments 
for treatment of insomnia using CBT-I. Patient screening began in November 2018 and 
continued until September 2019. Due to the low number of participants who were interested in 
participating in the study and who also met the treatment criteria, we changed our eligibility 
requirement within the patient screening timeframe from participants having to have completed 
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treatment 12 months prior to 3 months prior but no more than 5 years. This increased the 
recruitment rate but not near our target sample size. Recruitment continued until the potential 
participant pool had been exhausted with no new identifiable cases.  
A total of 45 survivors of cancer were screened for eligibility. Of these patients, 78% 
were excluded due to ineligibility. Geographical location of residence preventing treatment 
attendance was the primary reason for exclusion (27%), followed by no cognitive impairments 
(20%), male gender (17%), having completed all adjuvant cancer treatments more than 5 years 
prior (10%), a diagnosis of an alternative cancer to breast (10%), having previous experience 
with CBT-I (7%), a diagnosis of untreated obstructive sleep apnea (7%), and no present insomnia 
symptoms (3%). This left 15 patients who were potentially eligible for the study. We were able 
to successfully recruit 67% of these 15 patients to enrol in our study (five participants were 
unresponsive following initial contact). This resulted in a final sample of 10 survivors of breast 
cancer who consented to participate. With 45 participants screened and 10 being both eligible 
and completing baseline, this gave our study a recruitment feasibility of 22%. Detailed 
recruitment data (number of participants screened, eligible, consented, and dropouts) and reason 
for ineligibility are reported in Figure 3 (pg. 71). 
Objective 2: Acceptability of Research Protocol and Intervention 
Patient demographics are presented in Table 1 (p. 65). Women were an average age of 
50.8 (SD 6.84) with 18.2 (SD 3.62) years of education. Most of the women were either in a 
committed relationship or married (80%). The sample was predominantly diagnosed with stage 
II breast cancer (70%) and the time since diagnosis was on average 43.2 months (SD 18.2). 
About 60% of the women believed their cancer diagnosis or treatments caused their insomnia 
and the other 40% believed their insomnia worsened after diagnosis/treatment.  
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Treatment credibility and expectancy were determined prior to treatment using the 
Credibility/Expectancy Questionnaire (CEQ). See Table 2 (p. 67). Regarding credibility, when 
asked “At this point, how logical does the therapy offered to you seem?” the sample mean was 
8.10 (SD 1.10) out of a possible 9 (very logical). Regarding expectancy, when asked “At this 
point, how successful do you think this treatment will be in reducing your insomnia and 
cognitive impairment symptoms?”, the sample mean was 7.70 (SD .95) out of a possible 9 (very 
useful). Participants were highly confident they would recommend this treatment to a friend who 
experiences similar problems (Mean: 7.80 out of 9). By the end of the therapy period, 
participants expected their insomnia and cognitive impairment symptoms would improve by 
more than 70%. The overall credibility factor for this therapy for improving insomnia and 
cognitive impairment symptoms was rated at 7.87 out of 9 (87.4%) and the expectancy factor 
was 71%. 
The second objective was to determine if participants were able to complete the study 
protocol. Missing values analysis revealed that the percentage of missing data from questionnaire 
packages throughout the duration of the study was 6.98%. The majority of missing data came 
from a single participant (41%) who did not complete two assessment packages, a participant 
who did not complete one assessment package (21.8%) as well as some adherence issues with 
the consensus sleep diaries (10.42%) and actigraphs (12.92%). Due to the COVID-19 pandemic, 
actigraphy and CTT (6.77%) information was not accessible from two 6-month follow-up patient 
assessments that had to be conducted online. 
Adherence was calculated based on the number of participants who completed the 
assessment packages at all time points as well as those who completed treatment. A total of 50 
assessments were expected and 47 were actually completed, resulting in a response rate of 94% 
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for the full duration of the study. There was a downward trend in the number of assessments 
completed over the course of 8 months. At baseline and post-treatment, 100% of the assessments 
were completed, followed by 90% at 3 months and 80% at 6 months (See Figure 4, p. 72). As for 
the CBT-I treatment adherence 100% of participants who enrolled in the study completing all 7 
sessions of the treatment. 
 Attrition was defined as withdrawal from the study at any time point. The attrition rate 
for this study was 20%. One participant withdrew from the study following the post-treatment 
assessment due to emotional instability following the death of a family pet. Another participant 
was unresponsive to communications following the 3-month follow-up assessment. Missing 
values analysis imputation method was used for missing values.  
Objective 3: Treatment Effects and Durability  
To provide preliminary estimates for future randomized controlled trials, our third 
objective was to determine if scores on measures of PCI, objective cognitive impairment, sleep, 
fatigue and mood were associated with changes in insomnia symptomology following CBT-I 
treatment. A repeated measures analysis of variance (ANOVA) with pair-wise comparisons was 
performed at baseline, post-treatment, 3 months and 6 months for each of the symptoms, 
respectively. Results for the ANOVAs are presented in Table 3 (p. 68).  
At baseline, participants scored within the higher range of the PCI subscale [Mean: 28.6] 
with a range of 0 to 72. There was a large effect size and significant main effect of time for PCI 
over 8 months [F(3,27) = 10.81, p < .001, Ƞp2 = .546]. Pairwise comparisons revealed that there 
was a significant decrease in PCI from baseline to post treatment [Mean: 28.6 to 43.1; p = .006], 
3 months [Mean: 28.6 to 41.6; p = .003] and 6 months [Mean: 28.6 to 43.6; p = .002]. These 
changes represent both a statistically significant change and clinically meaningful change of 
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more than 5.9 points following treatment. PCI at post treatment was not significantly different 
than at 3 months [Mean: 43.1 to 41.6; p = .632] or 6 months [Mean: 43.1 to 43.6; p = .748] 
indicating that these changes were maintained at follow-up. There appeared to be no significant 
differences between PCI at 3 months and 6 months [Mean: 41.6 to 43.6; p = .434]. These results 
are presented in Figure 5 (p. 73). 
To provide a more in-depth analysis of cognitive impairment, we wanted to determine if 
measures of objective cognitive impairment in addition to PCI were sensitive to changes in 
insomnia symptomology following CBT-I treatment. Three tests (The HVLT-R, COWAT, and 
CTT) were used to capture the multifaceted nature of cognitive impairment and were compared 
to normative data using age and educational level to categorize as cognitively impaired. There 
was a small effect size and no significant main effect of time on verbal learning and memory 
[F(3, 27) = .238, p = .869, Ƞp2 =.026], a large effect size but no significant main effect of time on 
verbal fluency and executive functioning [F(3, 27) = .254, p = .254, Ƞp2 =.626], and a large 
effect size but no significant main effect of time on divided attention and processing speed [F(3, 
27) = 2.37, p = .093, Ƞp2 =.208]. These findings suggest that although statistically significant 
changes weren’t apparent in verbal learning and memory, verbal fluency and executive 
functioning, and divided attention and processing speed, there were small to large effects of time 
that may be of clinical significance. During baseline and throughout the duration of the study the 
average scores of each neuropsychological measure were within the non-cognitively impaired 
range. 
At baseline, participants were in the moderate severity range of clinical insomnia [Mean: 
19.4]. There was a large effect size and significant main effect of time for insomnia severity over 
8 months [F(3,27) = 25.48, p < .001, Ƞp2 = .739]. Pairwise comparisons revealed that there was a 
CBT-I FOR PCI    
 
32
significant decrease in insomnia severity from baseline to post treatment [Mean: 19.4 to 7.1; p < 
.001] which also represented a clinically meaningful change of  > 8.4 point reduction. Significant 
improvements were also noted in 3 months [Mean: 19.4 to 9.2; p < .001] and 6 months [Mean: 
19.4 to 12.1; p = .002]. While effects were largely maintained, there was some rebound of 
insomnia symptoms at 3 months [Mean: 7.1 to 9.2; p = .076] and 6 months [Mean: 9.2 to 12.1; p 
= .067].  
Baseline scores revealed participants scored in the normal and slightly below normal 
range for subjective sleep efficiency and objective sleep efficiency, respectively [Mean: 84.6, 
78.8]. There was a large effect size but no significant main effect of time for either subjective 
sleep efficiency [F(3,27) = 1.36, p = .275, Ƞp2 = .132] or objective sleep efficiency [F(3,27) = 
1.45, p = .249, Ƞp2 = .139] over 8 months. This suggests that statistically significant changes 
weren’t apparent in sleep efficiency however, there were large effects of time that may be of 
clinical significance. 
Based on the range of -24 to 96, participant’s baseline fatigue was in the moderate range 
[Mean: 43.0].  There was a large effect size and significant main effect of time for fatigue over 8 
months [F(3,27) = 5.49, p = .004, Ƞp2 = .379]. Pairwise comparisons revealed that there was a 
significant decrease in fatigue from baseline to post treatment [Mean: 43.0 to 24.4; p = .036], 3 
months [Mean: 43.0 to 21.5; p = .010] and 6 months [Mean: 43.0 to 25.0; p = .042]. These 
changes also represent a clinically meaningful change of 10.79 points. Fatigue at post treatment 
was not significantly different than at 3 months [Mean: 24.4 to 21.5; p = .548] or 6 months 
[Mean: 24.4 to 25.0; p = .875] suggesting decreases in fatigue were maintained at follow-up. 
There was no significant difference between fatigue at 3 months and 6 months [Mean: 21.5 to 
25.0; p = .402]. 
CBT-I FOR PCI    
 
33
At baseline, participants were in the subclinical range for depression [Mean: 7.9]. There 
was a large effect size and significant main effect of time on depression over 8 months [F(3,27) 
= 3.44, p = .031, Ƞp2 = .276]. Pairwise comparisons revealed that there were no significant 
differences between baseline and post treatment [Mean: 7.9 to 5.3; p = .101] or baseline to 3 
months [Mean: 7.9 to 5.4; p = .061], although significant decreases were apparent in depression 
from baseline to 6 months [Mean: 7.9 to 4.4; p = .035]. However, change in depression from 
baseline, post-treatment, 3 months and 6 months represents a clinically meaningful change of 1.3 
points. At post treatment depression was not significantly different than at 3 months [Mean: 5.3 
to 5.4; p = .929] or 6 months [Mean: 5.3 to 4.4; p = .337] indicating that changes in depression 
were maintained at follow-up. There were no significant differences between depression at 3 
months and 6 months [Mean: 5.4 to 4.4; p = .204]. At baseline, participants scored within the 
subclinical range for anxiety [Mean: 10.10]. There was a large effect size but no significant main 
effect of time on anxiety over 8 months [F(3,27) = 2.34, p = .095, Ƞp2 = .207]. However, a 
clinically meaningful change of 1.4 points was apparent in anxiety from baseline [Mean: 10.1], 
post-treatment [Mean: 8.4], 3 months [Mean: 7.7] and 6 months [Mean: 7.6]. This suggests that 
although statistically significant changes weren’t apparent in anxiety, there were large effects of 
time on anxiety that were clinically significant. 
In summary, baseline scores revealed participants entered the study with high levels of 
PCI, normal levels of cognitive functioning, moderately severe levels of insomnia, below normal 
levels of objective sleep efficiency, normal levels of subjective sleep efficiency, moderate levels 
of fatigue, and subclinical levels of depression and anxiety. Over the course of 8 months, there 
were statistically significant improvements in PCI, insomnia, fatigue and depression. Following 
treatment, improvements in PCI, insomnia and fatigue were all maintained at 3 and 6 months. 
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More importantly for this study, there were clinically significant improvements in PCI, insomnia, 
fatigue, depression and anxiety over 8 months. Lastly, there were large effect sizes over time for 
PCI (ES = .546), verbal fluency and executive functioning (ES = .626), divided attention and 
processing speed (ES = .208), insomnia (ES = .739), subjective sleep efficiency (ES = .132), 
objective sleep efficiency (ES = .139), fatigue (ES = .379), depression (ES = .276) and anxiety 
(ES = .207).   
Discussion 
This study assessed the feasibility, acceptability, and the preliminary effectiveness and 
durability of using CBT-I to reduce PCI in survivors of breast cancer. Regarding feasibility, the 
results indicated that out of 45 participants screened, 15 reported both insomnia and perceived 
cognitive impairment as well as met all other eligibility criteria, with 10 who enrolled. This 
provides 22% recruitment feasibility for this project, which indicates future randomized control 
trials will have to recruit approximately five times (80%) their intended sample size to obtain 
participants who are both interested and eligible. These findings will be very informative to 
subsequent designs as they can expect to recruit a much larger sample of interested participants 
than might have been previously expected. The literature states that insomnia affects 
approximately 60% of survivors of breast cancer (Savard et al., 2011) and cognitive impairments 
are reported in approximately 50% (Janelsins et al., 2017) but to our knowledge, this was the 
first study to estimate the prevalence of both insomnia and cognitive impairments (problems with 
attention, memory and concentration) in survivors of breast cancer. Based on our findings, about 
20% of survivors of breast cancer report issues with both insomnia and cognitive impairments, 
although future research should be conducted to identify the prevalence based on cancer stage, 
previous treatments, and underlying conditions. 
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The second aim of this study was to determine the acceptability of both the research 
project and the intervention for participants. Patient’s scores on the Credibility/Expectancy 
Questionnaire prior to treatment and adherence to study protocols were used as a proxy indicator 
of acceptability. No clear theoretical framework for acceptability was followed (e.g., Sekhon et 
al., 2017), and therefore some facets of acceptability may have been missed (e.g., affective 
attitude, ethicality, intervention coherence, opportunity costs, and self-efficacy). Prior to the 
intervention, participants on average thought the treatment was credible and expected positive 
outcomes. Participants were adherent to the treatment with 100% of participants who enrolled in 
the study completing the treatment. The completion rate of the intervention was higher than 
previous studies, where only 83% of survivors of cancer who had enrolled completed the 7-week 
intervention (Kamen et al., 2019). A plausible explanation for our large adherence rate to 
treatment could be the role of social support. Psychosocial factors such as social support predict 
both the adherence and response to CBT-I treatments, with those who have stronger social 
support networks being more likely to maintain improvements of the therapy (Kamen et al., 
2019). More positive partner statements are also associated with better treatment outcomes of the 
Insomnia Severity Index (Ellis et al., 2015). This explanation seems plausible as 80% of our 
sample were either married or in a committed relationship throughout the course of our study. 
Future studies should investigate the role of social support in treatment adherence as well as 
other social environment factors that may be contributing to the acceptability of the therapy such 
as the effects of co-sleeping, parenting, and other life events. Adherence to the assessments also 
seemed to be quite high based on the low frequency of dropouts (20%) from the study. This 
resulted in 47 out of 50 assessments being completed, a response rate of 94% for the full duration 
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of the study. These results build on existing evidence of low attrition rates (~15%) in CBT-I 
studies in women with breast cancer (Zhou et al., 2017).  
The third objective investigated if measures of PCI were sensitive to change following 
CBT-I treatment. A strong effect size of the treatment was noted for improvements in PCI, with 
changes being both clinically and statistically significant. These effects were largely maintained 
at 3 and 6 months, which indicates, that CBT-I may be successful in not only improving 
insomnia severity but also potentially PCI as well. However, prior to study initiation participants 
indicated they were very optimistic about the treatment and felt better about their cognitive 
performance following treatment. Expectancy effects may explain the improvements in PCI as 
there was no control group to account for such biases. This pilot trial is the first study to provide 
preliminary evidence of large effects of CBT-I on subjective cognitive impairment in survivors 
of breast cancer in particular. Our results are consistent with 14 other studies that were conducted 
in individuals with insomnia who did not have cancer that found small to moderate effect sizes of 
CBT-I on subjective cognitive impairment (Herbert et al., 2018). These results demonstrate 
promise of CBT-I as a plausible treatment for cognitive difficulties experienced following a 
cancer diagnosis and provide hope for future studies. 
We were also interested in whether measures of objective cognitive impairment in 
addition to PCI were sensitive to improvements in insomnia symptomology following CBT-I 
treatment. There were no statistically significant improvements in verbal learning and memory, 
verbal fluency and executive functioning and, divided attention and processing speed. 
Importantly, participant’s mean score based on age, sex and education were within the average 
range for verbal learning and memory, verbal fluency and executive functioning and, divided 
attention and processing speed at baseline which would make it difficult to demonstrate 
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improvements. These results are consistent with previous literature that has found inconsistencies 
between patient reports and neuropsychological cognitive measures (Hermelink, 2015). Our 
findings support the idea that the “chemo brain” may largely be a subjective experience with a 
strong emotional component involved (Hermelink, 2015). Previous literature has found PCI 
influences overall subjective wellness in cancer patients. With improvements in insomnia, 
fatigue, depression and anxiety in addition to subjective cognitive impairments noted in our 
study, the “chemo brain” being more of a subjective experience seems very plausible. These 
findings are consistent with other studies that have been conducted and found no significant 
improvements in objective cognitive functioning following CBT-I (Herbert et al., 2018). 
However, participants could have simply been having cognitive difficulties in areas that were not 
measured by our neuropsychological instruments. Although, there have been very few studies 
conducted to investigate the effectiveness of this therapy on cognitive functioning and like ours, 
the existing studies lacked power given the small sample sizes. Therefore, based on our sample 
size it is important to emphasize the large effect size of verbal fluency and executive functioning, 
and divided attention and processing speed that were noted over 8 months. Further research is 
warranted on this topic before deeming CBT-I as ineffective in improving cognitive impairment, 
with samples that show larger impairments at baseline.  
Consistent with previous findings (Johnson et al., 2016), clinical and statistical 
improvements in insomnia severity were noted with large effect sizes in survivors of breast 
cancer following CBT-I treatment and scores remained lower than baseline at 3 and 6 months 
following treatment; however, there was an linear increase in insomnia severity following 
treatment. A plausible explanation for this could be adherence to therapeutic recommendations 
following treatment. Manber et al. (2011) notes that better adherence to CBT-I treatment is 
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associated with lower insomnia scores following treatment. In particular, patients report that 
adhering to the behavioural recommendations of CBT-I can be quite difficult (Matthews et al., 
2013). These guidelines can be especially challenging to follow long-term as pleasant 
experiences such as sleeping in on weekends is not recommended in order to keep a consistent 
sleep and wake time and involves a large lifestyle change (Matthews et al., 2013). Where this 
study did not provide any incentive following treatment and no therapist to hold the patient 
accountable, it may have been harder for them to adhere to the treatment recommendations. This 
theory would explain the weakening of treatment effect over time, as without continued support 
from the therapist, patients may stop engaging in behaviours that are beneficial for sleep. Based 
on Spielman’s 3 P model (Spielman et al., 1987), what tends to predominately feed insomnia 
symptoms are perpetuating factors. These are behaviours those experiencing sleep difficulties 
following a precipitating event (e.g., stressful life event) do to compensate for loss of sleep (e.g., 
napping). Therefore, reinstating these perpetuating factors would increase the likelihood of 
insomnia symptoms returning.  
We did not observe a significant increase in either subjective or objective sleep 
efficiency. Although our findings were not statistically significant, our effect size was in line 
with previous research, showing large treatment effects of CBT-I on sleep efficiency (Johnson et 
al., 2016). It is possible that adherence may be to blame for the lack of significant findings as 
most of the missing data in the individual questionnaires were from sleep diaries and actigraphs. 
For the sleep diaries in particular, perhaps inaccurate recording of daily sleep impaired the utility 
of the data obtained. This would explain the lack of variability in sleep diary sleep efficiency 
scores throughout the course of the study. This theory would also provide support for why there 
seemed to be inconsistencies between subjective and objective measures of sleep efficiency in 
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survivors of breast cancer with insomnia, which is consistent with the literature (Moore et al., 
2015). These results also support our use of both an objective and subjective sleep efficiency 
measures in order to provide a more reliable measurement. Although statistically significant 
improvements were not apparent throughout the duration of the study, there were large effect 
sizes in sleep efficiency that provide optimistic preliminary evidence for future studies. 
In addition to insomnia symptoms, fatigue had also significantly decreased with a large 
effect size over 8 months, with improvements in fatigue following treatment being maintained 3- 
and 6-months following treatment. These findings are consistent with Fleming et al (2014) who 
found CBT-I effectively reduced clinical levels of fatigue related to cancer treatments as well. 
This is unsurprising as you would expect treatment programs designed to decrease insomnia 
would also yield improvements in highly co-occurring symptoms as well, especially those 
related to day-time functioning (Kim et al., 2018). 
 The current results indicate that depression symptomology significantly decreased over 
the course of 8 months but there were no apparent differences following treatment compared to 
baseline. Interestingly, there were also no statistically significant changes in anxiety 
symptomology over the course of the study. This is inconsistent with previous literature which 
has found CBT-I to be very effective in decreasing insomnia, depression and anxiety 
symptomology particularly in survivors of breast cancer (Fleming et al., 2014; Garland et al., 
2014). However, once scores had decreased following treatment, they remained consistently in 
the non-significant range. There also appeared to be large effect sizes and clinically meaningful 
changes in both anxiety and depression throughout the study. A possible explanation for these 
results is that participants did not show high levels of depression or anxiety at baseline, scoring 
in the subclinical range. With a range of scores between 0-10 out of a possible range of 0-21, 
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achieving statistical significance is difficult given the size of our current sample. Based on the 
large effect sizes and clinical significance, CBT-I demonstrates promise for reducing mood 
disturbance in the population in subsequent research. 
Strengths and Limitations  
 This study was the first of its kind to test whether we could improve the commonly 
reported symptom of “chemo brain” in survivors of breast cancer using CBT-I. The primary 
strength of this study was its ability to provide valuable information for stronger future research 
designs. Given the small sample size and detection of improvement in PCI, our results show 
promise for future randomized controlled trials. Secondly, the current study used the best 
available measures of symptoms. Subjective measures were used to determine psychological 
well-being symptoms which are best assessed by self-report (Haberer et al., 2013) while 
subjective and objective measures of insomnia, sleep and cognitive functioning were used, 
giving us confidence in the accuracy of the results (Aili et al., 2017; Savard & Ganz, 2016; 
Morin, 2003). 
There were also a number of limitations to our study, the first being the small sample 
size. With such a small sample, it is difficult to obtain representativeness from the population 
making it hard to determine generalizability as well as draw any firm conclusions from the 
results. However, this is not the purpose of a feasibility study. Future studies should try to obtain 
a larger, more heterogeneous sample, including those living in rural communities as well. A 
small sample size also decreased the power of our study but we were still able to find significant 
differences with a low powered study. To adapt to the small sample limitation, we also reported 
effect sizes and clinically meaningful change scores. As well, given the number of statistical tests 
performed to evaluate preliminary efficacy, future studies should correct for alpha-spending 
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function, which was no appropriate given the exploratory nature of this study. Secondly, due to 
the single arm design of this study with no control group, we are unable to rule out the effect of 
time on patients PCI. Improvement in PCI could have been attributed to time effects rather than 
the treatment provided. Control conditions are also the principle method used to ensure internal 
validity by removing overlapping variance of unwanted variables in experimental research. 
Selection biases therefore may have occurred as well with self-selected highly motivated women 
may have led to larger improvements following CBT-I treatment. As well as a possible demand 
characteristic may have been present with participants expecting to notice improvements given 
the high expectancy effects at pre-intervention. Specifically, in the treatment of insomnia, meta-
analyses indicate a reliable placebo effect (Yeung et al., 2018). Experimenter effects are 
important to consider as well given a systematic review that examined 146 meta-analyses that 
included 1,346 trials reported that a lack of blinding within trials resulted in a 25% exaggeration 
in the effect sizes of subjective outcomes (Wood et al., 2008). Although future randomized 
controlled trials will be able to control for some of these confounds, future studies should 
potentially include a healthy control group as well to rule out practice effects on measures that do 
not have multiple forms suitable for repeated testing (Wefel et al., 2011). Of particular concern is 
the potential impact of administering numerous instruments to a population vulnerable to 
attention/concentration/memory problems. This may have led to incorrect recall of symptoms as 
well as potential fatigue effects that could bias the results. However, neuropsychological tests 
were spaced out between self-report questionnaires to limit this effect. This study was also 
unable to control for potential confounds such as mood or stress on PCI due to the small sample 
size. Subsequent designs should control overlapping variance to increase the accuracy of the 
results. The amount of missing data was also of concern as missing value analysis was conducted 
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to estimate scores based on previous data. Future studies should try to limit missing data as much 
as possible to conserve reliability of their findings. Lastly, this non-experimental research design 
provides the inability to infer causation. Although we have identified that a relationship exists 
between improvement in insomnia and PCI, this relationship is purely correlational. The two 
may simply coexist but the extensive literature suggests that improvement in one may have an 
indirect effect on the other as well. 
Conclusion  
Our study was the first study to investigate the feasibility and acceptability of using a 
gold-standard treatment for insomnia on subjective cognitive complaints in this population. 
Although recruitment yielded difficulties, CBT-I was associated with improvements in not only 
PCI but also objective cognitive functioning, sleep efficiency, insomnia, fatigue, depression and 
anxiety. The current pilot trial has important implications for future studies investigating 
treatment modalities for the psychological well-being of survivors of cancer. Subsequent 
research should examine the effectiveness of this treatment on a larger scale with a more 
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Table 1  
Summary of Demographic Characteristics 
 N % 
 10 100 
Age   
      Mean (SD) 50.8 (6.84)  
      Range (42-63)  
Race   
      White 10 100 
      Non-white 0 0 
Body Mass Index   
      Underweight (< 18.5) 0 0 
      Normal weight (18.5 – 24.9) 3 30.0 
      Overweight (25 – 29.9) 5 50.0 
      Obese (> 30) 2 20.0 
Years of Education   
      Mean (SD) 18.2 (3.62)  
      Range (12-23)  
Employment   
      Full-time 5 50.0 
      Part-time 2 20.0 
      Unemployed/Retired 3 30.0 
Relationship Status   
      Single 1 10.0 
      Committed relationship/Married 8 80.0 
      Divorced 0 0 
      Widowed 0 0 
      Other 1 10.0 
Comorbid Health Conditions   
      Obstructive Sleep Apnea (Treated)  2 20.0 
      Depression 1 10.0 
      Inflammatory conditions 6 60.0 
      Crohn’s Disease 2 20.0 
      Bone Diseases (Osteoporosis/Osteopenia) 2 20.0 
* Women could have more than one of these conditions   
Cancer Stage   
      I 2 20.0 
      II 7 70.0 
      III 1 10.0 
Months Since Treatment Completion   
      Mean (SD) 9.6 (3.84)  
      Range (6-15)  
Months Since Cancer Diagnosis   
      Mean (SD) 43.2 (18.2)  






      Range (24-84)  
Treatments   
      Surgery 10/10 100 
      Chemotherapy 9/10 90.0 
      Radiation  8/10 80.0 
      Hormonal Therapy 8/10 80.0 
      Antibody Therapy 4/10 40.0 
     * Women could have received more than one of these treatments   
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Table 2  
Credibility/Expectancy Questionnaire 
  
 Mean(SD) (Range) % 
        10  100 
Question 1:     
At this point, how logical does the therapy offered to you seem? 8.10(1.10) (6-9) 100 
    
Question 2:    
At this point, how successfully do you think this treatment will be 
in reducing your insomnia and cognitive impairment symptoms? 
7.70(.95) (6-9) 100 
    
Question 3:    
How confident would you be in recommending this treatment to a 
friend who experiences similar problems? 
7.80(1.23) (6-9) 100 
    
Question 4:    
By the end of the therapy period, how much improvement in your 
insomnia and cognitive impairment symptoms do you think will 
occur? 
71.0(19.7) (20-90) 100 
    
Credibility Factor (Questions 1-3) 7.87  100 
    
Expectancy Factor (Question 4) 71.0  100 




Repeated Measures Analysis of Variance of Patient Symptoms 
 
  
                     Baseline Post Treatment 3 Months 6 Months Time Effect 
Effect 
Size 
                 
    Mean(SD) Mean(SD) Mean(SD) Mean(SD) F (df) [p] Ƞp
2 
Perceived Cognitive  




Impairment       
Verbal Learning & Memory 
(HVLT-R) 92.50(17.97) 91.70(16.79) 88.30(32.28) 89.40(12.68) 
.238 (3,27) 
[.869] .026 
Executive Verbal Functioning 
(COWAT) 42.00(10.10) - - 42.50(11.18) 
.254 (3,27) 
[.254] .626 
Divided Attention &              
Processing Speed (CTT) 76.37(20.26) 66.97(17.88) 71.11(16.66) 66.87(11.03) 
2.37 (3,27) 
[.093] .208 
Insomnia (ISI) 19.44(3.66) 7.10(3.81) 9.20(3.49) 12.10(3.93) 25.48 (3,27) [<.001] .739 
Objective Sleep Efficiency 
(Actigraphy) 78.84(12.25) 80.51(9.62) 81.94(10.79) 85.99(3.35) 
1.45 (3,27) 
[.249] .139 
Subjective Sleep Efficiency 
(CSD) 84.60(7.03) 89.90(5.97) 80.32(17.41) 84.85(7.21) 
1.36 (3,27) 
[.275] .132 
Fatigue (MFSI-SF) 43.00(18.81) 24.40(15.41) 21.50(12.59) 25.00(9.68) 5.49 (3,27) [.004] .379 
Depression (HADS-D) 7.90(3.45) 5.30(2.83) 5.40(1.84) 4.40(1.90) 6.08 (3,27) [.036] .276 
Anxiety (HADS-A) 10.10(4.36) 8.20(3.91) 7.70(1.70) 7.60(3.20) 2.34 (3,27) [.095] .207 




Figure 1. Treatment conceptual model. The interactions between cancer treatments, 
psychological side effects, sleep disturbance and physical side effects on cognitive impairment. 
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Figure 2. Study design.  
  




Figure 3. Recruitment flowchart of eligible participants. Feasibility of suitable women with 
breast cancer who reported both insomnia and cognitive impairments and acceptability of the 
research project including completion rates of questionnaire packages. 
  




Figure 4. Acceptability of research study in survivors of breast cancer. All participants who 
enrolled in the study completed treatment. One dropout following treatment resulted in a 
decrease in retention at 3 and 6 months. Another dropout following 3 months resulted in decrease 





























Figure 5. Change in insomnia and perceived cognitive impairment (PCI) following treatment. 
Comparison of insomnia (A) and PCI (B) symptoms at baseline, post treatment, 3 months and 6 
months. Insomnia and PCI symptoms significantly improved following treatment and were 
maintained 6 months following treatment (p < .001). There were no significant differences 
between post-treatment, 3-month and 6-month scores for both insomnia and PCI. Higher ISI 
score indicates worse insomnia severity. Higher FACT-COG indicates better PCI. Data were 


















































Weekly CBT-I Description: 
 
Week One: Week one involved gaining information from participants with respect to medication 
use, medical problems, addressing any immediate concerns/problems with participation (e.g., 
adverse events, symptoms, illnesses, or new stressors), discussing the participant’s sleep 
schedule and discussing motivation and general compliance issues of the therapy. Using this 
information, the therapist was able to formulate an impression of the type and subtype of 
insomnia and determine modifiable factors that relate to the predisposing, precipitating, 
perpetuating factors and conditioning relevant to the development and maintenance of insomnia. 
At the end of the session, the therapist gave the participant a sleep diary to fill out for the week, 
reinforcing its importance, and confirmed the next appointment the following week.  
Week Two: Session two was more in depth with regards to the participant’s sleep schedule and 
involved reviewing the sleep diary to identify any mismatch between the sleep opportunity and 
the sleep ability. By reviewing the patient’s sleep diary from the previous week the therapist was 
able to calculate sleep onset latency, sleep efficiency (i.e., current sleep ability vs. hours spent in 
bed), total sleep time, wake after initial sleep onset, early morning awakenings and total time in 
bed. These scores were used to provide an individualized sleep program for the upcoming weeks. 
This allowed the therapist to introduce sleep education and explain the 4-P model of insomnia 
(modifiable factors that relate to the predisposing, precipitating, perpetuating factors and 
conditioning relevant to the development and maintenance of insomnia). The therapist then used 
this information to prescribe sleep restriction and stimulus control therapy while providing the 
rationale behind the prescription. This involved: 1.) Setting a strict wake up time for every day of 
the week, regardless of number of hours slept. 2.) Establishing a 60-90-minute relaxation buffer 
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zone before bed in dim light, avoiding the use of backlit devices. 3.) Setting a bedtime but only if 
sleepy and restricting the bed use to only sleep and sex. 4.) Encouraging to get out of bed and 
return to buffer zone if participant cannot fall or fall back to sleep within 15-20 minutes to again 
engage in relaxing activities. 5.) Try to deter participants from napping during the day. Similar to 
week one, the therapist gained information from participants with respect to medication use, 
medical problems, addressed any immediate concerns/problems with participation (e.g., adverse 
events, symptoms, illnesses, or new stressors) and discussed motivation and general compliance 
issues of the therapy. The session ended by reinforcing the importance of the sleep diary and new 
time to bed/time out of bed, providing the patient with a hard copy of the individualized sleep 
program and confirming the next appointment for the following week. 
Week Three: Session three began with reviewing the patient’s sleep diary from the previous 
week and calculating sleep variables. Same as previous weeks, the therapist identified changes to 
medication use, medical problems, addressed any immediate concerns/problems with 
participation (e.g., adverse events, symptoms, illnesses, or new stressors) and discussed 
motivation and general compliance issues of the therapy. Stimulus control and sleep restriction 
procedures were continued, and participants were provided with a sleep hygiene handout, which 
was reviewed to develop a plan for behavior change if necessary. The session ended by 
reinforcing the importance of the sleep diary, prescribing a new time to bed/time out of bed, and 
confirming the next appointment for the following week. 
Week Four: Session four began with reviewing the patient’s sleep diary from the previous week 
and calculating sleep variables. Same as previous weeks, the therapist identified changes to 
medication use, medical problems, addressed any immediate concerns/problems with 
participation (e.g., adverse events, symptoms, illnesses, or new stressors) and discussed 
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motivation and general compliance issues of the therapy. Stimulus control and sleep restriction 
procedures were continued, and participants were introduced to and suggested to practice 
relaxation strategies if necessary (e.g., deep breathing, imagery, progressive muscle relaxation). 
The session ended by reinforcing the importance of the sleep diary, prescribing a new time to 
bed/time out of bed, and confirming the next appointment for the following week. 
Week Five: Session five began with reviewing the patient’s sleep diary from the previous week 
and calculating sleep variables. Same as previous weeks, the therapist identified changes to 
medication use, medical problems, addressed any immediate concerns/problems with 
participation (e.g., adverse events, symptoms, illnesses, or new stressors) and discussed 
motivation and general compliance issues of the therapy. Stimulus control and sleep restriction 
procedures were continued, and the therapist conducted cognitive therapy by identifying 
catastrophic thoughts, discuss why the worry may happen, introduced cognitive techniques and 
designated a worry time earlier in the evening. The session ended by reinforcing the importance 
of the sleep diary, prescribing a new time to bed/time out of bed, and confirming the next 
appointment for the following week. 
Week Six: Session six began with reviewing the patient’s sleep diary from the previous week 
and calculating sleep variables. Same as previous weeks, the therapist identified changes to 
medication use, medical problems, addressed any immediate concerns/problems with 
participation (e.g., adverse events, symptoms, illnesses, or new stressors) and discussed 
motivation and general compliance issues of the therapy. Stimulus control and sleep restriction 
procedures were continued, and the therapist reviewed any strategies that need further 
reinforcement. The session ended by reinforcing the importance of the sleep diary, prescribing a 
new time to bed/time out of bed, and confirming the next appointment for the following week. 
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Week Seven: The final session began with reviewing the patient’s sleep diary from the previous 
week and calculating sleep variables. The therapist reviewed the overall process, provided the 
patient with a relapse prevention handout to remind them how to maintain gains, discussed 
sleep restriction guidelines for if insomnia returns, discussed prophylaxis (how insomnia 
develops etc.) and elaborated on how gains will continue with proper stimulus control. 
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FACT-Cog PCI Subscale: 
FACT-Cognitive Function (Version 3)  
Below is a list of statements that other people with your condition have said are important. 
Please circle or mark one number per line to indicate your response as it applies to the past 7 
days. 












1. I have had trouble forming thoughts 
 
 
0 1 2 3 4 
2. My thinking has been slow 
 
 
0 1 2 3 4 
3. I have had trouble concentrating 
 
 
0 1 2 3 4 
4. I have had trouble finding my way to a 
familiar place 
 
0 1 2 3 4 
5. I have had trouble remembering where 
I put things, like my keys or my wallet 
 
0 1 2 3 4 
6. I have had trouble remembering new 
information, like phone numbers or 
simple instruction 
0 1 2 3 4 
7. I have had trouble recalling the name 
of an object while talking to someone 
 
0 1 2 3 4 
8. I have had trouble finding the right 
word(s) to express myself 
 
0 1 2 3 4 
9. I have used the wrong word when I 
referred to an object 
 
0 1 2 3 4 
10. I have had trouble saying what I 
mean in conversations with others 
 
0 1 2 3 4 
11. I have walked into a room and 
forgotten what I meant to get or do there 
 
0 1 2 3 4 







12. I have had to work really hard to pay 
attention or I would make a mistake 
 
0 1 2 3 4 
13. I have forgotten names of people  
soon after being introduced 
 
0 1 2 3 4 
14. My reactions in everyday situations 
have been slow 
 
0 1 2 3 4 
15. I have had to work harder than usual 
to keep track of what I was doing 
 
0 1 2 3 4 
16. My thinking has been slower than 
usual 
 
0 1 2 3 4 
17. I have had to work harder than usual 
to express myself clearly 
 
0 1 2 3 4 
18. I have had to use written lists more 
often than usual so I would not forget 
things 
0 1 2 3 4 
19. I have trouble keeping track of what I 
am doing if I am interrupted 
 
0 1 2 3 4 
20. I have trouble shifting back and forth 
between different activities that require 
thinking 
0 1 2 3 4 




Insomnia Severity Index: 
1. Please rate the current (i.e., last 2 weeks) severity of your insomnia problem(s). 
 
2. How satisfied/dissatisfied are you with your current sleep pattern? 
 
3. To what extent do you consider your sleep problem to interfere with your daily functioning 
(e.g. daytime fatigue, ability to function at work/daily chores, concentration, memory, mood, 
etc.) 
 
4. How noticeable to others do you think your sleeping problem is in terms of impairing the 
quality of your life? 
 
5. How worried/distressed are you about your current sleep problem? 
 
 None Mild Moderate Severe Very 
a. Difficulty falling asleep:  0 1 2 3 4 
b. Difficulty staying asleep: 0 1 2 3 4 
c. Problem waking up to early: 0 1 2 3 4 
Very satisfied Satisfied Neutral Dissatisfied Very dissatisfied 
0 1 2 3 4 
Not at all 
interfering 
A little Somewhat Much Very much 
interfering 
0 1 2 3 4 
Not at all 
noticeable 
A little Somewhat Much Very much 
noticeable 
0 1 2 3 4 
Not at all 
worried 
A little Somewhat Much Very much 
worried 
0 1 2 3 4 
